Chronic Inflammatory Demyelinating Polyneuropathy

>

The NeurologyLive® Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) clinical focus page is a concentrated place for the latest information on the care and management of patients with CIDP. This page includes podcasts, videos and expert interviews, and news about the latest study and clinical trial findings, FDA actions, and clinical guideline updates.

Latest News

Pete Salzmann, MD, MBA  (Credit: LinkedIn)
Immunovant Reports Positive Phase 3 and Phase 2b Results for Batoclimab in Myasthenia Gravis and CIDP

March 19th 2025

The company recently announced positive topline results from its phase 3 study in patients with MG and initial data from its phase 2b study in patients with CIDP, both assessing batoclimab.

Rituximab Shows No Effect Over Placebo in Preventing CIDP Disease Deterioration
Rituximab Shows No Effect Over Placebo in Preventing CIDP Disease Deterioration

February 12th 2025

Case Report Reveals Promising Efficacy of Ofatumumab as Long-Term Treatment in Relapsing CIDP
Case Report Reveals Promising Efficacy of Ofatumumab as Long-Term Treatment in Relapsing CIDP

February 11th 2025

Hubertus Axer, MD  (Credit: ResearchGate)
Clinical and Ultrasound Scores Helps Differentiate CIDP from Diabetic Polyneuropathy

January 30th 2025

Low-Dose Rituximab Regimen Claims Superiority Over Conventional Treatment in CIDP
Low-Dose Rituximab Regimen Claims Superiority Over Conventional Treatment in CIDP

January 28th 2025

Video Interviews

More News

© 2025 MJH Life Sciences

All rights reserved.